Respiration 2012;84:12–13
(DOI:10.1159/000335838)

Back to the Roots of Chronic Obstructive Pulmonary Disease: The Severity of Respiratory Impairment Matters

Antonelli-Incalzi R.
Area di Geriatria, Servizio di Fisiopatologia Respiratoria, Università Campus Bio Medico, Roma, Italia
email Corresponding Author


 Outline


 goto top of outline Abstract

No abstract available

Copyright © 2012 S. Karger AG, Basel


goto top of outline  

Chronic obstructive pulmonary disease (COPD) is a complex disease and, as such, it is commonly considered worthy of a comprehensive approach with a rapidly expanding list of ‘omics’ joining the broad series of factors, mainly non-respiratory factors, expected to shed light on its phenotypic variability and its clinical course. This dramatic conceptual and practical effort is commendable because it tries to identify associated diseases clustering under the umbrella definition COPD. However, it should not distract from classical, direct indicators of COPD severity in favor of multidimensional indexes, which not always sustain longer testing. Such an approach would carry the risk of disregarding prognostically important information, mainly in patients with an acute exacerbation. Indeed, since 1995 it is well known that the alveolar-arterial difference in oxygen, an index of gas exchange efficiency, is second only to age as prognostic indicator in patients with acutely exacerbated COPD [1]. On the other hand, multidimensional indexes are intended for long-term prediction and, thus, are unlikely to improve the prognostic definition of acutely exacerbated COPD with regard to classical indexes of respiratory impairment. In this perspective, the study by Matkovic et al. [2] in this issue of Respiration clearly shows that hypoxemia, hypercapnia and frequent exacerbations identify patients more likely to experience a composite adverse outcome. Neither BODEx nor dose-modified indexes could improve the AUC of the ROC model when substituted for history of exacerbation in the previous year, with hypoxemia and hypercapnia being the other two components of the model. This finding points to a simpler prognostic model being preferable to a more articulated one, at least in the acute care setting. Moreover, it suggests that the collected history of exacerbation is the core prognostic information shared by these indexes. Finally, it stresses the role that frequent exacerbations, which may represent a phenotypic variant of COPD [3], have in conditioning the course of the disease.

The observation by Matkovic et al. [2 ] is to some extent biased by the relatively small sample size (n = 155), and, as the authors correctly acknowledge, the lack of information on selected and prognostically important comorbidities or complications of COPD such as chronic cor pulmonale [4]. However, its main limitation is an inclusion criterion shared with the vast majority of studies on COPD: the selection of patients able to satisfactorily perform spirometry likely guarantees that patients really having COPD are included, but it excludes a consistent fraction of patients, frequently with advanced COPD or important comorbidities, unable to perform spirometry. This is especially true for a population with a mean age of 70 years. In fact, even in optimal settings, 1 of 4 COPD subjects >64 years could not meet ATS/ERS standards for the quality of spirometry, and even the FEV6, a simpler surrogate measure of FVC, could not be obtained in 1 of 5 [5,6]. Thus, the true problem of this and almost all studies lies in the patients with COPD studied as a representative COPD population. Even large pharmacological trials have adopted so stringent exclusion criteria, ranging from long-term oxygen therapy to any comorbidity that could preclude participation in the study or interfere with study results, to select a population poorly representative of the ‘usual’ COPD population [7,8,9].

Despite these limitations, the study by Matkovic et al. [2] extended our view on COPD by stressing the short-term prognostic role of direct indicators of respiratory impairment and COPD severity. This reminds us that, at least when exacerbated, COPD affects the health status primarily as a respiratory disease. Then, a careful assessment and an optimal treatment of the respiratory problem is what the patient needs, at least in this clinical context. Accordingly, the caring physician should point at the origins of COPD. Conceptualizing complex disease entities might help to understand the place of COPD among chronic conditions and to clarify components of the umbrella definition, if any, but it is unlikely to provide prognostically important information and, possibly, improve management in the acute care setting.


 goto top of outline References
  1. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G: Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98:272–277.
  2. Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A, Miravitlles M: Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration 2012;84: 17–26.

    External Resources

  3. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128–1138.
  4. Incalzi RA, Fuso L, Rosa MD, Napoli AD, Basso S, Pagliari G, Pistelli R: Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999;99:1600–1605.
  5. Bellia V, Pistelli R, Catalano F, Antonelli- Incalzi R, Grassi V, Melillo G, Olivieri D, Rengo F: Quality control of spirometry in the elderly. The SA.R.A. study. SAlute Respiration nell’Anziano: Respiratory Health in the Elderly. Am J Respir Crit Care Med 2000;161:1094–1100.
  6. Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, Pedone C, Antonelli-Incalzi R: Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax 2008;63:60–66.
  7. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–1554.
  8. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, Torch Investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
  9. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van-Molken M, Beeh KM, Rabe KF; Fabbri LM, POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093–1103.

 goto top of outline Author Contacts

Raffaele Antonelli-Incalzi
Area di Geriatria, Servizio di Fisiopatologia Respiratoria
Università Campus Bio Medico, Via Alvaro del Portillo 5
IT–00128 Rome (Italy)
E-Mail r.antonelli@unicampus.it


 goto top of outline Article Information

Published online: March 7, 2012
Number of Print Pages : 2
Number of Figures : 0, Number of Tables : 0, Number of References : 9


 goto top of outline Publication Details

Respiration (Official Journal of the European Association for Bronchology and Interventional Pulmonology (EAB) and the Swiss Society for Pneumology (SGP))

Vol. 84, No. 1, Year 2012 (Cover Date: June 2012)

Journal Editor: Bolliger C.T. (Cape Town)
ISSN: 0025-7931 (Print), eISSN: 1423-0356 (Online)

For additional information: http://www.karger.com/RES


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.